Literature DB >> 437919

Enhancement of tumor outgrowth by tumor-associated blocking factors.

K E Hellström, I Hellström.   

Abstract

Transplanted lines of 3-methylcholanthrene (MCA)-induced BALB/c sarcomas were used for experiments in which tumors were mechanically suspended in Waymouth's culture medium, the suspensions centrifuged and filtered and the remaining cell-free "tumor fluids" (TF) tested for activity in vitro and in vivo. TF were found to inhibit ("block") cell-mediated cytotoxicity to tumor target cells in vitro with specificity for each tumor tested and even at high dilutions (1:1,000-1:10,000). In vivo, TF enhances the outgrowth of subcutaneously transplanted tumors in non-immune syngeneic mice. This enhancement had both specific and non-specific components, with the non-specific component being most apparent. Enhancement was best demonstrated when the TF were inoculated together with the tumor inocula. In one of two experiments in which TF were given intraperitoneally, specific enhancement was seen, whereas in the other, inhibition of tumor outgrowth was observed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 437919     DOI: 10.1002/ijc.2910230315

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Thymic factor-induced reduction of pulmonary metastases in mice with FSA-1 fibrosarcoma.

Authors:  V J Tomazic; C R Sacasa; A Loftus; C S Suter; G E Elias
Journal:  Clin Exp Metastasis       Date:  1988 Jan-Feb       Impact factor: 5.150

2.  Inhibition of sensitized leukocyte's in vitro reactivity by circulating immune complexes in prostate cancer.

Authors:  R Bhatti; M Shaw; P Ray
Journal:  Experientia       Date:  1987-08-15

3.  Immunoselection of tumor variants resistant to antibody-mediated cytotoxicity. Their immunologic and metastatic characterization.

Authors:  J R Starkey; W C Davis; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Immunologic enhancement of experimental metastasis in the rat.

Authors:  J R Starkey; S S Ristow; T L McDonald; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 5.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

6.  TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.

Authors:  E A Grimm; W L Crump; A Durett; J P Hester; S Lagoo-Deenadalayan; L B Owen-Schaub
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Administration of cyclophosphamide changes the immune profile of tumor-bearing mice.

Authors:  Pu Liu; Jade Jaffar; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

8.  Opposing changes in electrokinetic potential of spleen cells induced by factors from different tumour supernatants.

Authors:  D Vaillier; J Vaillier
Journal:  Immunology       Date:  1981-09       Impact factor: 7.397

9.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.